Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors
Authors:
Open Access
- 14 May 2026
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 34 (8) , 4670-4686
Abstract
No abstract availableKeywords
Funding Information
- Syöpäsäätiö
- Sigrid Juséliuksen Säätiö
- Punainen Risti Veripalvelu
- Jane ja Aatos Erkon Säätiö
- Research Council of Finland
This publication has 42 references indexed in Scilit:
- Performance of serum CD163 as a marker of fibrosis in patients with NAFLDDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021
- Interaction of adenovirus with antibodies, complement, and coagulation factorsFEBS Letters, 2019
- The impact of infection and inflammation in oncologic 18F-FDG PET/CT imagingBiomedicine & Pharmacotherapy, 2019
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell TherapyMolecular Therapy-Oncolytics, 2017
- The innate immune response during liver inflammation and metabolic diseaseTrends in Immunology, 2013
- Rapid Kupffer cell death after intravenous injection of adenovirus vectorsMolecular Therapy, 2006
- Lipid Emulsions Potently Increase Transgene Expression in Hepatocytes after Adenoviral TransferMolecular Therapy, 2006
- Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectorsMolecular Therapy, 2003
- Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in LiverMolecular Therapy, 2001